BACKGROUND: Pacemaker-dependent patients with left ventricular dysfunction benefit from upgrade to cardiac resynchronization therapy (CRT). Those at low risk for ventricular tachyarrhythmias may benefit similarly from upgrade to a CRT-defibrillator or CRT-pacemaker. OBJECTIVE: To determine whether coronary artery disease (CAD), because of associated scar that supports reentry, predicts higher risk of appropriate shocks in pacemaker-dependent patients upgraded to a CRT-defibrillator. METHODS: We grouped 157 pacemaker-dependent patients with left ventricular ejection fraction (LVEF) ≤35%, no prior sustained ventricular arrhythmias, and conventional pacemakers upgraded to CRT-defibrillators according to the presence (n = 75) or absence (n = 82) of significant CAD. Overall survival, risk of appropriate shocks and antitachycardia pacing, complications related to high-power system components, and LVEF and end-systolic volume changes were contrasted between groups. RESULTS: Patients with CAD had more comorbidities and exhibited increased mortality during a follow-up of 59 ± 30 months (hazard ratio 2.55; 95% confidence interval 1.49-4.36; P = .001). Of 12 patients with appropriate shocks, 11 had CAD. Time to first shock, antitachycardia pacing, and tachyarrhythmia therapy were significantly shorter in patients with CAD (P < .01). The risk of an appropriate shock in patients without CAD was 1 per 362 person-years compared with 1 shock per 26 person-years in patients with CAD. Complications specific to high-energy device components necessitated another procedure in 32 (20%) patients. LVEF improvement and end-systolic volume reduction were similar between groups. CONCLUSIONS: Among pacemaker-dependent patients with no prior ventricular arrhythmias upgraded from a pacemaker to a CRT-defibrillator, patients without significant CAD have fewer comorbidities, longer survival, and low risk of appropriate shocks than do patients with CAD. CRT-pacemakers may be appropriate in such patients without CAD.
BACKGROUND: Pacemaker-dependent patients with left ventricular dysfunction benefit from upgrade to cardiac resynchronization therapy (CRT). Those at low risk for ventricular tachyarrhythmias may benefit similarly from upgrade to a CRT-defibrillator or CRT-pacemaker. OBJECTIVE: To determine whether coronary artery disease (CAD), because of associated scar that supports reentry, predicts higher risk of appropriate shocks in pacemaker-dependent patients upgraded to a CRT-defibrillator. METHODS: We grouped 157 pacemaker-dependent patients with left ventricular ejection fraction (LVEF) ≤35%, no prior sustained ventricular arrhythmias, and conventional pacemakers upgraded to CRT-defibrillators according to the presence (n = 75) or absence (n = 82) of significant CAD. Overall survival, risk of appropriate shocks and antitachycardia pacing, complications related to high-power system components, and LVEF and end-systolic volume changes were contrasted between groups. RESULTS:Patients with CAD had more comorbidities and exhibited increased mortality during a follow-up of 59 ± 30 months (hazard ratio 2.55; 95% confidence interval 1.49-4.36; P = .001). Of 12 patients with appropriate shocks, 11 had CAD. Time to first shock, antitachycardia pacing, and tachyarrhythmia therapy were significantly shorter in patients with CAD (P < .01). The risk of an appropriate shock in patients without CAD was 1 per 362 person-years compared with 1 shock per 26 person-years in patients with CAD. Complications specific to high-energy device components necessitated another procedure in 32 (20%) patients. LVEF improvement and end-systolic volume reduction were similar between groups. CONCLUSIONS: Among pacemaker-dependent patients with no prior ventricular arrhythmias upgraded from a pacemaker to a CRT-defibrillator, patients without significant CAD have fewer comorbidities, longer survival, and low risk of appropriate shocks than do patients with CAD. CRT-pacemakers may be appropriate in such patients without CAD.
Authors: Barbara Bellmann; Bogdan G Muntean; Tina Lin; Christopher Gemein; Kathrin Schmitz; Patrick Schauerte Journal: Anatol J Cardiol Date: 2015-11-30 Impact factor: 1.596